Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 8/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247579 | 0.81 | MIF (0.50) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL29022653 | 0.80 | TAAR1 (0.47) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL462795 | 0.80 | TAAR1 (0.47) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL8763999 | 0.79 | MIF (0.48) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL11747749 | 0.77 | MIF (0.46) | MIFTAAR1TRPA1AOC3RIPK1 | |
| SCHEMBL6956846 | 0.77 | MIF (0.53) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL25332409 | 0.76 | LMNA (0.47) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL3119964 | 0.76 | LMNA (0.47) | MIFTAAR1TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL11746136 | 0.76 | TAAR1 (0.42) | MIFTAAR1TRPA1AOC3RIPK1 | |
| SCHEMBL11751211 | 0.76 | TAAR1 (0.47) | MIFTAAR1TRPA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330451-B1 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6653478-B2 | Psychological disorders; hypotensive agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-1330451-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002055514-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | AVPR2, NPY1R, AVPR1B | MIF 1570/4885TAAR1 367/4885TRPA1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.